September 2, 2020 /

NS Pharma Announcement of VILTEPSO™ (August 26, 2020)

NS Pharma Announcement of VILTEPSO™ (viltolarsen) – A New FDA-Approved Treatment for Patients With Duchenne Amenable to Exon 53 Skipping (August 26, 2020 Webinar)

NS Pharma joined PPMD for a webinar on August 26, 2020 to provide an update about VILTEPSO™ from Ben Yungher, PhD, NS Pharma’s Medical Science Liaison, and its associated patient support program from Randy McGonigal, NS Pharma’s Director of Market Access.

Posted on September 2, 2020

Join Our Mailing List